Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the <scp>TRIUMPH</scp> registrational clinical trials
By recruiting participants with shared disease exposures, the TRIUMPH program will assess the safety and efficacy of retatrutide for the treatment of adults with obesity and two of its common complications-OSA and OA.
Authors
- K. Giblin
- Carel Wynand le Roux (ORCID: https://orcid.org/0000-0001-5521-5445)
- Amy Lalonde (ORCID: https://orcid.org/0000-0002-7471-6787)
- Qiwei Wu (ORCID: https://orcid.org/0000-0002-6179-9755)
- Nadia Ahmad (ORCID: https://orcid.org/0000-0003-3607-0740)
- M. Angelyn Bethel (ORCID: https://orcid.org/0000-0002-7754-6584)
- Lee M. Kaplan (ORCID: https://orcid.org/0000-0002-6301-2696)
- Virend K. Somers
- David John Hunter (ORCID: https://orcid.org/0000-0003-3197-752X)
Institutions
- University College Dublin (IE)
- The University of Sydney (AU)
- Boston Biomedical Research Institute (US)
- Mayo Clinic (US)
- Eli Lilly (United States) (US)
- Royal North Shore Hospital (AU)
- Institute for Musculoskeletal Health (AU)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1111/dom.70209
- Citations
- 2
- Primary Topic
- Obstructive Sleep Apnea Research
- Type
- article
- Field-Weighted Citation Impact
- 2.33
Funders
- Eli Lilly and Company